ArticleJournal of clinical medicine2019
The Clinical Significance of Programmed Death-1, Regulatory T Cells and Myeloid Derived Suppressor Cells in Patients with Nontuberculous Mycobacteria-Lung Disease.
Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Lower airway dysbiosis in nontuberculous mycobacteria-positive bronchiectasis is associated with neutrophil extracellular trap-predominant severe phenotypes.American journal of respiratory and critical care medicine · 2026Article
- Genetic Susceptibility to Nontuberculous Mycobacterial Pulmonary Disease: Is It the Chicken or the Egg?American journal of respiratory and critical care medicine · 2025Article
- Association between immunity and antimicrobial treatment resistance in patients with Mycobacterium avium complex pulmonary disease: a multicenter observational study.BMC infectious diseases · 2025Observational
- Innate and Adaptive Lymphocytes in Non-Tuberculous Mycobacteria Lung Disease: A Review.Frontiers in immunology · 2022Review
- Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy.International journal of nanomedicine · 2022Review
- Immunotherapy of targeting MDSCs in tumor microenvironment.Frontiers in immunology · 2022Review
- Roles of the Exosomes Derived From Myeloid-Derived Suppressor Cells in Tumor Immunity and Cancer Progression.Frontiers in immunology · 2022Review
- Host-Pathogen Interactions Operative duringImmune network · 2021Review
- Non-tuberculous mycobacteria immunopathogenesis: Closer than they appear. a prime of innate immunity trade-off and NTM ways into virulence.Scandinavian journal of immunology · 2021Review
- DNA Methylation Profiling for the Diagnosis and Prognosis of Patients with NontuberculousCurrent issues in molecular biology · 2021Article
- The double-edged sword of Tregs in M tuberculosis, M avium, and M absessus infection.Immunological reviews · 2021Review
- Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients.Journal of clinical medicine · 2021Article
- Myeloid-derived suppressor cells-new and exciting players in lung cancer.Journal of hematology & oncology · 2020Review
- Roles of HMGB1 in regulating myeloid-derived suppressor cells in the tumor microenvironment.Biomarker research · 2020Review
- The New Frontier of Host-Directed Therapies forFrontiers in immunology · 2020Review
- Recombinant interleukin-7 treatment of refractoryTherapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundIncreasing expression of programmed death-1 (PD-1) in patients with nontuberculous mycobacteria lung disease (NTM-LD) has been reported, but its role in clinical characteristics and outcomes remains unclear.
methodsWe enrolled 96 participants, including 46 with
resultsThe percentage of PD-1 on CD4
conclusionAs markers of immune tolerance, PD-1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.